The company expired its plan on June 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | 0.00% | +3.68% | -47.78% |
30/06 | Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired. | CI |
24/06 | Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.78% | 2.94Cr | |
+20.17% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.77TCr | |
-17.74% | 2.03TCr | |
-15.17% | 1.68TCr | |
-15.21% | 1.56TCr | |
+11.91% | 1.48TCr | |
-47.10% | 1.46TCr | |
+54.50% | 1.44TCr |
- Stock Market
- Equities
- ENLV Stock
- News Enlivex Therapeutics Ltd.
- Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired.